Tinengotinib
- Generic Name
- Tinengotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19ClN6O
- CAS Number
- 2230490-29-4
- Unique Ingredient Identifier
- WZ9TJ0L9Y8
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06457919
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsCholangiocarcinoma
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Registration Number
- NCT06370013
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
- Conditions
- Cholangiocarcinoma
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05948475
- Locations
- 🇺🇸
UCLA Medical Center, Santa Monica, California, United States
🇺🇸The University of Chicago Hospitals, Chicago, Illinois, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Conditions
- Gallbladder CancerProstate CancerThyroid CancerAdvanced Solid TumorCholangiocarcinomaTriple Negative Breast CancerGastric CancerBiliary Tract CancerHER2-negative Breast CancerSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT05253053
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳Fudan Univisity Shanghai Cancer Center, Shanghai, China
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
- Conditions
- CholangiocarcinomaFGFR2 FusionFGFR2 Gene MutationFGFR1 AlterationFGFR3 Alteration
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04919642
- Locations
- 🇺🇸
Methodist Dallas Medical Center, Dallas, Texas, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Conditions
- Prostate CancerAdvanced Solid TumorGallbladder CancerCholangiocarcinomaBladder CancerTriple Negative Breast CancerSmall-cell Lung CancerHER2-negative Breast CancerThyroid CancerSarcoma
- Interventions
- Combination Product: Nab-Paclitaxel
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 203
- Registration Number
- NCT04742959
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
- Conditions
- Advanced Solid TumorsTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03654547
- Locations
- 🇨🇳
Cancer Hopital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.